AKT1 and hepatocellular carcinoma: A study using sorafenib-resistant HCC cells has shown that sorafenib reduces miR-21 expression in the nucleus and promotes lncRNA small nucleolar RNA host gene 1 (SNHG1) expression, leading to the activation of the AKT pathway, contributing to drug resistance [168].